Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 29Lymphoma, B-Cell 6Lymphoma, Follicular 5Lymphoma, Mantle-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 1

Interventions

Rituximab 165Cyclophosphamide 163fludarabine phosphate 95Peripheral Blood Stem Cell Transplantation 88Filgrastim 72Etoposide 65Mycophenolic Acid 63Whole-Body Irradiation 62Cytarabine 59Cyclosporine 53Melphalan 52Tacrolimus 47Busulfan 43Radiotherapy 42Lenalidomide 42Bortezomib 40ibrutinib 39fludarabine 39Methotrexate 38Antilymphocyte Serum 38Carmustine 37Bendamustine Hydrochloride 35Vincristine 33Doxorubicin 32Dexamethasone 32Granulocyte Colony-Stimulating Factor 29Prednisone 26Cord Blood Stem Cell Transplantation 25venetoclax 22obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Mantle-Cell × polatuzumab vedotin × Clear all
NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

Phase 1/2 Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Academic and Community Cancer Research United

Phase 2 Terminated
3 enrolled 11 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05868395 2024-05-29

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Medical University of Vienna

Phase 2 Recruiting
16 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT04913103 2021-06-04

CLSGMCLPOLA

Czech Lymphoma Study Group

Phase 2 Not yet recruiting
21 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡